Cumulative incidence of infection and infection density. Cumulative incidence of infection and infection prevalence within 100 days following idecabtagene vicleucel (ide-cel) infusion. (A) Cumulative incidence of first infection by type of infection (viral, bacterial, and fungal) among the total cohort (N = 52) over 100 days post ide-cel infusion. Patients were censored at the time of last follow-up (maximum of 100 days). Competing events were defined as disease relapse or progression and death. Two patients had concurrent bacterial and fungal infections. (B) Number of infections among the 28 patients with any infection annotated by type of infection (viral, bacterial, and fungal).